Sugi Predict

Sugi Predict / Compounds / SCHEMBL2204713

SCHEMBL2204713

SCHEMBL2204713

CC(C)(C)[Si](C)(C)OCNc1ccccc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 2/20 0.38
▸ ALDH1A1 P00352 2/20 0.38
▸ MAOA P21397 1/20 0.34
▸ MAOB P27338 1/20 0.34
▸ BACE1 P56817 1/20 0.34
▸ L3MBTL1 Q9Y468 1/20 0.33
▸ MEN1 O00255 2/20 0.33
▸ KMT2A Q03164 2/20 0.33
▸ SIGMAR1 Q99720 1/20 0.33
▸ KCNH3 Q9ULD8 1/20 0.33
▸ NPSR1 Q6W5P4 1/20 0.33
▸ NPC1 O15118 1/20 0.33
▸ TSHR P16473 1/20 0.33
▸ RAB9A P51151 1/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.33
▸ CYP1A2 P05177 1/20 0.33
▸ CYP3A4 P08684 1/20 0.33
▸ CYP2C9 P11712 1/20 0.33
▸ CYP2C19 P33261 1/20 0.33
▸ LTA4H P09960 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22498329 0.87 CYP1A2 (0.36) MAPTBACE1CYP1A2CYP3A4CYP2C9
SCHEMBL2599179 0.82 MAPT (0.44) MAPTALDH1A1L3MBTL1KCNH3BUB1
SCHEMBL31017573 0.82 APP (0.33) —
SCHEMBL22691805 0.80 FBP1 (0.34) MAPTSIGMAR1CYP1A2CYP3A4CYP2C9
SCHEMBL21496091 0.80 MAPT (0.43) MAPTALDH1A1MAOAMAOBL3MBTL1
SCHEMBL12488340 0.80 MAPT (0.50) MAPTALDH1A1L3MBTL1KCNH3NPC1
SCHEMBL22414320 0.78 MAPT (0.48) MAPTALDH1A1L3MBTL1KCNH3CYP1A2
SCHEMBL1069533 0.76 MAPT (0.40) MAPTALDH1A1MAOAMAOBL3MBTL1
SCHEMBL4616628 0.76 MAPT (0.40) MAPTALDH1A1MAOAMAOBL3MBTL1
SCHEMBL10199640 0.75 KMT2A (0.44) MAPTMAOAMEN1KMT2ASIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114191428-B Antibody-drug conjugates based on eribulin and methods of use 卫材研究发展管理有限公司 2024-09-24 — — CN disclosed
US-8569495-B2 Anthelmintic agents and their use INTERVET INTERNATIONAL B.V. (NL) 2013-10-29 — — US disclosed
US-7981880-B2 3-(aminomethyliden) 2-indolinone derivates and their use as cell proliferation inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-07-19 — — US disclosed
US-20110021506-A1 ANTHELMINTIC AGENTS AND THEIR USE INTERVET INTERNATIONAL B.V. (NL) 2011-01-27 — — US disclosed
US-20090105216-A1 3- (AMINOMETHYLIDEN) 2-INDOLINONE DERIVATES AND THEIR USE AS CELL PROLIFERATION INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-04-23 — — US disclosed
WO-2009011850-A2 NOVEL THERAPEUTIC COMPOUNDS ABBOTT LABORATORIES (US) 2009-01-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110021506-A1 ANTHELMINTIC AGENTS AND THEIR USE ACHE, ABCB11, MPO MAPT 1648/4885ALDH1A1 864/4885MAOA 1937/4885
US-20090105216-A1 3- (AMINOMETHYLIDEN) 2-INDOLINONE DERIVATES AND THEIR USE AS CELL PROLIFERATION INHIBITORS MKI67, CCNI, CCNA1 MAPT 2645/4885ALDH1A1 170/4885MAOA 375/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.